NCT03756389

Evaluation of Topical Application of BMX-010 in Subjects With Rosacea

An Exploratory Trial to Evaluate the Clinical Effectiveness of a Topical Application of BMX-010 in Subjects With Rosacea

• Status: Suspended
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: BioMimetix JV, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an exploratory Phase 2 trial of BMX-010 in patients with Rosacea which will be conducted in two parts. Up to 210 subjects with Rosacea will be enrolled.

Detailed description

Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug. Up to 60 subjects will be enrolled in this part. Part B is designed to be a randomized, double-blind trial studying the optimal formulation, strength, and dosing frequency of BMX-010 as determined in Part A, compared to Placebo. Up to 150 subjects will be enrolled in this part. In both parts, adult subjects with Rosacea will be enrolled.

Conditions

• Rosacea

Interventions

Type	Name	Description
DRUG	BMX-010	Safety and efficacy of BMX-010 in topical treatment of rosacea.

Timeline

• Start date: 2018-01-03
• Primary completion: 2024-09-01
• Completion: 2025-03-01
• First posted: 2018-11-28
• Last updated: 2022-09-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study